script.reportAU
Register
← The record

Peginterferon Alfa-2b

Recommended GastroenterologyFirst-line line

treatment of chronic hepatitis C in patients who have not previously received interferon treatment, with or without ribavirin

1
Submissions
2005–05
On the record
$15k–45k
ICER range
1 sourced ICER · 2005
ICER stated
Cost basis

Decisions on record

2 decisions
  • Meeting Mar 2003 Recommended A combination therapy for hepatitis C no PSD
  • Meeting Mar 2002 Recommended Hepatitis C no PSD

Access path

1 submission · public record
  1. Nov 2005
    Recommended · restricted

    vs Pegatron therapy in patients with stage F1/A2-A3, F2, F3…

  2. PBS listing
RecommendedDeferredNot recommended

Cost-effectiveness

1 sourced ICER · 2005

Decision context

Populationpatients with no or mild hepatitis C

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Nov 2005 Recommended · restricted Pegatron therapy in patients with stage F1/A2-A3, F2, F3 and F4 fibrosis $15k–45k RCT · SVR

Similar precedents

By decision profile
Peginterferon Alfa-2a, Ribavirin86%Peginterferon Alfa-2a80%Ribavirin And Peginterferon Alfa-2b76%Boceprevir And Ribavirin And Peginterferon Alfa-2b75%Boceprevir75%Ribavirin74%Simeprevir71%Telaprevir71%

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to no or mild hepatitis C, whereas TGA label includes all patients with compensated liver disease regardless of fibrosis stage.